Expression of ErbB-1 and ErbB-2 in meningioma.
Meningiomas are benign intracranial tumours treated by neurosurgical resection. Residual or recurrent tumour may be treated with radiotherapy. Effective molecular therapy for residual and recurrent meningiomas is currently unavailable. We tested meningiomas for In-ErbB-1 and ErbB-2, and the levels were compared to normal brain, peripheral nerve, glioblastoma multiforme and vestibular schwannoma. Our findings with immunohistochemistry and western blot analysis indicate a level of ErbB-1 similar to normal peripheral nerve, but a high expression of ErbB-2 similar to the vestibular schwannoma and glioblastoma multiforme. These preliminary results implicate a potential role for ErbB-2 in the benign tumourigenesis of meningioma consistent with the theoretical hierarchical interactions of homodimers of ErbB-2 that may be associated with low signal transduction.
Wickremesekera
Agadha
A
Department of Neurosurgery, Wellington Hospital, Riddiford Street, Newtown, Wellington 6021, New Zealand. Agadha.Wickremesekera@ccdhb.org.nz
Hovens
Christopher M
CM
Kaye
Andrew H
AH
D066246:ErbB Receptors / Q000096:biosynthesis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008577:Meningeal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008579:Meningioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010525:Peripheral Nerves / Q000378:metabolism; D055503:Protein Multimerization / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics
D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases